Key Highlights

  • Shares trading down 3.66% to $0.76 in today's session.
  • Trading Volume reached 89.17 thousand shares, with a 52-week range of $0.69 to $3.78.
  • The company reported an EPS of negative $0.70.
  • New Phase 1 data compared the company's topical cream against oral treatment in healthy men.

Phase 1 Data Presented at Sexual Medicine Conference

Daré Bioscience, Inc. (NASDAQ:DARE), a San Diego-based women's health biotech, presented Phase 1 data comparing its topical Sildenafil Cream against oral sildenafil in healthy men at a sexual medicine conference. The study showed substantially lower systemic drug exposure with the topical version, supporting further development of the cream as a potential treatment for female sexual arousal disorder, a condition with no FDA-approved drug treatment today.

Lower Systemic Exposure Highlighted as Key Finding

At the tested topical dose, mean maximum plasma concentration was roughly 187-fold lower compared to the oral dose, while overall systemic exposure was about 33 to 34-fold lower. All treatment-related side effects reported in the study were mild, with no serious adverse events recorded.

Stock Remains Well Below Its 52-Week High

Shares continue to trade near the lower end of their 52-week range of $0.69 to $3.78, with an EPS of negative $0.70 reflecting the company's pre-revenue stage on this program. Despite today's data presentation, shares moved lower, suggesting investors may be waiting for later-stage trial results before reassessing the stock.

Outlook: Regulatory Pathway Still Ahead

The company is continuing to advance Sildenafil Cream toward a regulatory pathway that allows it to rely in part on existing safety and efficacy data for approved products. With additional trial data still needed, the stock's near-term direction may continue to hinge on further clinical updates.